DICOTnews September 2026
The summer months have been eventful for Dicot Pharma. A successful rights issue has significantly strengthened our financial position, while we have also made substantial progress in our preparations for the start of the Phase 2b clinical study of LIB-01. We continue to take important steps toward our long-term goal of developing an entirely new treatment for erectile dysfunction.
Elin Trampe, CEO of Dicot Pharma
Oversubscribed Rights Issue
Our unit offering in June was subscribed to 134%, raising SEK 231 million before transaction costs. We view this strong outcome as a clear vote of confidence in Dicot Pharma’s strategy and potential. Among other things, the proceeds secure financing for the Phase 2b clinical study.
In San Diego
In June, we participated in BIO International in San Diego, the leading partnering conference in the life science industry. We held many productive meetings with potential partners, including both follow-up discussions with existing contacts and introductions to new stakeholders.
Full Speed Ahead for the Phase 2b Study
The study is designed to evaluate the efficacy of LIB-01 at different dose levels following repeated administration, and we remain on track to initiate the Phase 2b study during 2026. Read more about the latest details and regulatory progress here:
Press release: Clinical Trial Application submitted in the EU
Q2 Report Released
An eventful and strategically important quarter. Watch a recorded presentation of the second quarter, followed by a Q&A session, and find more details in the interim report here:
New CFO
Cecilia Driving has been appointed Chief Financial Officer, succeeding Björn Petersson, who has served the company on a consultancy basis. Read more about Cecilia’s extensive experience, her perspective on the CFO role, and what attracted her to Dicot Pharma:
Three Abstracts Selected
Three abstracts on LIB-01 have been selected for oral presentation at the leading Sexual Medicine Society of North America conference in October. Having three abstracts chosen for oral presentation is a remarkable achievement.